Next generation sequence analysis for mitochondrial disorders
Open Access
- 23 October 2009
- journal article
- research article
- Published by Springer Nature in Genome Medicine
- Vol. 1 (10) , 1-10
Abstract
Background: Mitochondrial disorders can originate from mutations in one of many nuclear genes controlling the organelle function or in the mitochondrial genome (mitochondrial DNA (mtDNA)). The large numbers of potential culprit genes, together with the little guidance offered by most clinical phenotypes as to which gene may be causative, are a great challenge for the molecular diagnosis of these disorders. Methods: We developed a novel targeted resequencing assay for mitochondrial disorders relying on microarray-based hybrid capture coupled to next-generation sequencing. Specifically, we subjected the entire mtDNA genome and the exons and intron-exon boundary regions of 362 known or candidate causative nuclear genes to targeted capture and resequencing. We here provide proof-of-concept data by testing one HapMap DNA sample and two positive control samples. Results: Over 94% of the targeted regions were captured and sequenced with appropriate coverage and quality, allowing reliable variant calling. Pathogenic mutations blindly tested in patients' samples were 100% concordant with previous Sanger sequencing results: a known mutation in Pyruvate dehydrogenase alpha 1 subunit (PDHA1), a novel splicing and a known coding mutation in Hydroxyacyl-CoA dehydrogenase alpha subunit (HADHA) were correctly identified. Of the additional variants recognized, 90 to 94% were present in dbSNP while 6 to 10% represented new alterations. The novel nonsynonymous variants were all in heterozygote state and mostly predicted to be benign. The depth of sequencing coverage of mtDNA was extremely high, suggesting that it may be feasible to detect pathogenic mtDNA mutations confounded by low level heteroplasmy. Only one sequencing lane of an eight lane flow cell was utilized for each sample, indicating that a cost-effective clinical test can be achieved. Conclusions: Our study indicates that the use of next generation sequencing technology holds great promise as a tool for screening mitochondrial disorders. The availability of a comprehensive molecular diagnostic tool will increase the capacity for early and rapid identification of mitochondrial disorders. In addition, the proposed approach has the potential to identify new mutations in candidate genes, expanding and redefining the spectrum of causative genes responsible for mitochondrial disorders.Keywords
This publication has 46 references indexed in Scilit:
- Mutations in NDUFAF3 (C3ORF60), Encoding an NDUFAF4 (C6ORF66)-Interacting Complex I Assembly Protein, Cause Fatal Neonatal Mitochondrial DiseaseThe American Journal of Human Genetics, 2009
- A Nonsense Mutation in COQ9 Causes Autosomal-Recessive Neonatal-Onset Primary Coenzyme Q10 Deficiency: A Potentially Treatable Form of Mitochondrial DiseaseThe American Journal of Human Genetics, 2009
- Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencingNature Biotechnology, 2009
- The Spliceosome: Design Principles of a Dynamic RNP MachineCell, 2009
- Mutation of C20orf7 Disrupts Complex I Assembly and Causes Lethal Neonatal Mitochondrial DiseaseThe American Journal of Human Genetics, 2008
- Pathogenic Mitochondrial DNA Mutations Are Common in the General PopulationThe American Journal of Human Genetics, 2008
- A Mitochondrial Protein Compendium Elucidates Complex I Disease BiologyCell, 2008
- The in-depth evaluation of suspected mitochondrial diseaseMolecular Genetics and Metabolism, 2008
- Genome-wide in situ exon capture for selective resequencingNature Genetics, 2007
- Human Coenzyme Q10 DeficiencyNeurochemical Research, 2006